Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) had its target price lowered by research analysts at Piper Sandler to $3.00 in a report issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 476.92% from the stock’s current price.
Several other research analysts also recently commented on MIST. Wall Street Zen upgraded Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. Cantor Fitzgerald assumed coverage on Milestone Pharmaceuticals in a research note on Thursday, August 20th. They issued an “overweight” rating and a $3.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $5.83.
Check Out Our Latest Research Report on MIST
Milestone Pharmaceuticals Price Performance
Shares of Milestone Pharmaceuticals stock opened at $0.52 on Monday. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13. Milestone Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.06. The company has a fifty day moving average of $0.80 and a 200-day moving average of $1.31. The stock has a market capitalization of $64.74 million, a price-to-earnings ratio of -0.69 and a beta of 1.07.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $1.00 million. Milestone Pharmaceuticals had a negative net margin of 1,860.76% and a negative return on equity of 305.75%. Equities research analysts expect that Milestone Pharmaceuticals will post -0.84 EPS for the current year.
Institutional Trading of Milestone Pharmaceuticals
Several large investors have recently modified their holdings of the business. HighTower Advisors LLC increased its position in Milestone Pharmaceuticals by 100.0% during the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock valued at $27,000 after purchasing an additional 10,000 shares during the period. Valeo Financial Advisors LLC raised its holdings in Milestone Pharmaceuticals by 12.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock worth $127,000 after purchasing an additional 16,000 shares in the last quarter. Bay Rivers Group lifted its position in shares of Milestone Pharmaceuticals by 55.9% in the 2nd quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock worth $62,000 after purchasing an additional 16,722 shares during the period. Guardian Wealth Advisors LLC NC lifted its position in shares of Milestone Pharmaceuticals by 21.1% in the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after purchasing an additional 59,200 shares during the period. Finally, Pinnacle Wealth Planning Services Inc. purchased a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth about $68,000. 86.18% of the stock is owned by institutional investors.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Further Reading
- Five stocks we like better than Milestone Pharmaceuticals
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
